Pharmafile Logo
Pharmafocus logo
Advanced Search

Pfizer

Showing 15 posts of 894 posts found.

Pfizer headquarters

Pfizer pays $63m for generics portfolio

January 5, 2011
Sales and Marketing Akorn, Akorn-Strides, Pfizer, Strides Arcolab, generics, injectables

Pfizer has bolstered its generics portfolio, paying around $63 million for 22 drugs. The company will buy 16 Abbreviated New …

News

VTE trial boost for Pfizer and BMS’ apixaban

December 31, 2010
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Pfizer, VTE, apixaban, enoxaparin, venous thromboembolism

Pfizer and Bristol-Myers Squibb’s oral anticoagulant apixaban has shown benefits over a standard injectable treatment for venous thromboembolism in a …

News

Pfizer expands Lipitor recall

December 24, 2010
Manufacturing and Production Lipitor, Pfizer, manufacturing compliance, recalls

Pfizer has been forced to recall another 19,000 bottles of its cholesterol-lowering drug Lipitor in the US after consumers reported …

News
Pfizer's New York headquarters

Pfizer withdraws hypertension drug Thelin

December 14, 2010
Sales and Marketing PAH, Pfizer, Thelin, liver damage, liver toxicity, patient safety, pulmonary arterial hypertension, sitaxentan

Pfizer has suffered a blow to its drug development programme with the withdrawal of pulmonary arterial hypertension (PAH) brand Thelin …

News

Pfizer: WikiLeaks claims “preposterous”

December 10, 2010
Research and Development Nigeria, Pfizer, Trovan, WikiLeaks, ceftriaxone, clinical trial safety, industry reputation

Pfizer has dimissed as “preposterous” the claims it hired investigators to uncover evidence of corruption by a top government official …

News
Dr Steve Yang

Double blow to Pfizer’s emerging markets strategy

December 10, 2010
Business Services, Sales and Marketing David Simmons, Ian Read, Jean-Michel Halfon, Jeffrey Kindler, Pfizer, Steve Yang, emerging pharma markets, recruitment

Pfizer has lost two senior executives with key roles in its emerging markets strategy. The departure of the company’s head …

News

Hormone therapy drugs ‘increase heart disease risk’

December 10, 2010
Research and Development AstraZeneca, Hormone therapy, Novartis, Pfizer, aromatase inhibitors, breast cancer, tamoxifen

Three aromatase inhibitors could increase the risk of heart disease in postmenopausal women with breast cancer, according to new data. …

News

Trial hitch for Pfizer’s leukaemia drug submission plans

December 7, 2010
Research and Development, Sales and Marketing CML, Gleevec, Glivec, Pfizer, bosutinib, chronic myeloid leukaemia

Pfizer is pressing ahead with plans to submit bosutinib for European approval despite the chronic myeloid leukaemia drug missing its …

News

Surprise exit for Pfizer chief executive Jeffrey Kindler

December 6, 2010
Manufacturing and Production, Research and Development, Sales and Marketing Ian Read, Jeffrey Kindler, Lipitor, Pfizer, Wyeth, executive succession

Pfizer’s chief executive Jeffrey Kindler has unexpectedly stepped down, saying his time at the helm of the world’s largest pharmaceutical …

News
Blog footer

Digital Pharma: Pfizer expands online clinic and aims for viral hit

November 29, 2010
Medical Communications Digital Pharma blog, ManMOT, Pfizer, patient information

Pfizer’s digital initiative targeting men who are reluctant to visit a GP is to be extended until May next year …

News
Pfizer headquarters

Pfizer submits Gaucher drug to EMA

November 29, 2010
Sales and Marketing Cerezyme, EMA, Gaucher disease, Genzyme, Pfizer, Protalix BioTherapeutics, Shire, Vpriv, taliglucerase alfa

Pfizer and partner Protalix BioTherapeutics have submitted a marketing application to European regulator the EMA for their Gaucher disease candidate …

News

The renal cell carcinoma market: Votrient to challenge Sutent’s lead

November 25, 2010
Sales and Marketing GSK, GlaxoSmithKline, Pfizer, Sutent, Votrient, rcc, renal cell carcinoma

After decades of no new medicines emerging to treat renal cell carcinoma, no fewer than five new drugs were approved …

Feature

Brain cancer vaccine to move into phase III

November 24, 2010
Research and Development, Sales and Marketing Celldex, Pfizer, brain cancer, glioblastoma

Celldex will press ahead with large-scale trials of its vaccine treatment for brain cancer after encouraging phase II results. The …

News

Pfizer’s axitinib impresses in head-to-head trial with Nexavar

November 22, 2010
Research and Development, Sales and Marketing Kidney cancer, Nexavar, Pfizer, axitinib, mRCC, metastatic renal cell carcinoma

Pfizer’s axitinib has impressed in phase III trials assessing its efficacy as a second line treatment for renal cell carcinoma. …

News

Pfizer establishes new US research network

November 17, 2010
Research and Development, Sales and Marketing BiodiscoveryTherapeutics, MedImmune, Pfizer

Pfizer has established a new network of research partnerships with its Global Centers for Therapeutic Innovation. The Centers is a …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026